Press Release

Approval for sale of Jublia in KoreaMay 17, 2017

Tokyo, May 17, 2017 - Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) announced that Kaken's licensing partner, Dong-A ST Co., Ltd. (“Dong-A ST”, head office Dongdaemun-gu, Seoul; President Min Jang Seong) obtained approval on May 16, 2017, from Korea's Ministry of Food and Drug Safety (MFDS) for the sale of Jublia, a topical formulation drug for Onychomycosis (generic name: efinaconazole; product name in Japan: Clenafin®) in Korea.

Kaken and Dong-A ST concluded a license agreement on May 31 2016 granting Dong-A ST exclusive rights for the development and sale of Jublia in Korea, and Dong-A ST filed an application for approval. Dong-A ST will begin the sale of Jublia in Korea in the end of May 2017.

About Dong-A ST

  • Company name
    Dong-A ST Co., Ltd.
    President
    Min Jang Seong
    Head Quarter
    Seoul

Back to list